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Abstracts 397obstructive pulmonary disease (COPD), diabetes mellitus, coronary artery
disease (CAD), lack of statins on treatment (1 point each). We calculated
the total risk score as the sum of all risk factors’ points, and grouped them
into 4 categories. Another 334 asymptomatic patients were extracted from
two tertiary care medical centers to derive a validation cohort (VC). The
derivation cohort (DC) and VC were clinically similar in terms of age (74 vs.
72 years) and gender (males 66% vs. 63%). Among risk factors, they
differed only for CAD (20% vs. 30% P < 0.001) and statin therapy (44% vs.
60% P < 0.001). They were comparable as per diabetes (29% vs. 24%
P ¼ 0.09), mean creatinine (1.13 vs. 1.1 mg/dL, P ¼ 0.58) and COPD (13.2%
vs. 10.5%, 0.21).
Results: Median follow up was 56 months for DC and 65 months for VC.
Long term mortality was comparable among DC and VC: overall survival
was 98.9  0.4% vs. 96.7  0.1% at 1 year; 92.7  1.1% vs. 91  1.6% at 3
years and 84.7  1.7% vs. 85.2  2% at 5 years.When comparing groups, 5
years survival rate was 97  1.5% for patients with score 0e3, 88.4  2.2%
for score 4e7, 69.6  4.7% for score 8e11, and 48.1  13.5% for score
12 (P < 0.0001) in the DC (ﬁg. 1). Similarly in the VC we found a
95.5  2% 5 years survival for score 0e3, 89.5  2.7% for score 4e7,
65  6.1% for score 8e11 and 44.8  14.1% for score 12 (P < 0.0001).
Conclusion: Our scoring system is a simple, 6 variables clinical tool for
prediction of post-operative life expectancy. The score showed to predict
adequately the long-term survival in a validation cohort from two different
medical centers. Patients with a score >8 have a poor long term survival,
and the advantage of CEA in this subgroup is questionable.We believe that
our score may help clinicians while selecting asymptomatic patients who
would beneﬁt from CEA.
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Introduction: Randomized trials have reported contradictory ﬁndings
regarding outcomes after carotid artery stenting (CAS) versus carotid
endarterectomy (CEA). Despite this, the 2011 American Heart Association
(AHA) guidelines expanded CAS indications, partly because of data from the
Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), but
also because of improving outcomes in Industry-sponsored ‘high risk for
CEA’ CAS Registries. The aim of the current systematic review was to see
whether there was a parallel reduction in procedural risk after CAS in
contemporary administrative dataset registries.
Methods: PubMed/Medline, Embase and Cochrane databases were
systematically searched from January 1, 2008 until February 23, 2015 for
administrative dataset registries reporting outcomes after both CEA and
CAS.
Results: Twenty-one registries reported outcomes after >1,500,000
procedures. CAS had similar stroke/death rates with CEA in one registry
involving ‘average risk’ asymptomatic and in two registries involving
‘average risk’ symptomatic patients. Stroke/death rates after CAS were
signiﬁcantly higher than CEA in 9/15 registries involving ‘average risk’
asymptomatic and in 11/18 registries involving ‘average risk’ symptomatic
patients. In ﬁve registries, CAS was associated with higher stroke/death
rates than CEA for both symptomatic and asymptomatic patients, but
formal statistical comparison was not reported. CAS was associated with
stroke/death rates that exceeded risk thresholds recommended by the AHA
in 9/15 registries involving ‘average risk’ asymptomatic patients and in 13/
18 registries involving ‘average risk’ symptomatic patients. In 5/18 regis-
tries, the procedural risk after CAS in ‘average risk’ symptomatic patients
exceeded 10%.
Conclusion: Data from contemporary administrative dataset registries
suggest that stroke/death rates following CAS remain signiﬁcantly higher
than after CEA and frequently exceed accepted AHA thresholds. In this
systematic review, there was no evidence of a sustained decline in pro-
cedural risk after CAS. The extremely high published risks in some
symptomatic registries suggest that clinical governance is not being ap-
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Introduction: Clopidogrel has provided signiﬁcant reduction in major
vascular events in patients with peripheral artery disease (PAD), particu-
larly among those following PTA. Clopidogrel antiplatelet effects differ
according to genotype ABCB1 and CYP2C19, establishing normal, inter-
mediate and poor metabolizers; and good or bad carriers. Intermediate and
poor metabolizers (CYP2C19 *1/*2,*2/*2) and bad transporters (ABCB1TT)
are responsible for the poor antiplatelet drug response. These poly-
morphisms have been associated with differences in clopidogrel response
in acute coronary syndrome patients but effects in peripheral artery dis-
ease are still understudied.
To determine the onset of ischemic vascular events requiring reopera-
tion of the affected limb or amputation in patients undergoing PTA (+/-
stent) during one year after treatment and to study the association with
the presence of genetic polymorphisms CYP2C19 and ABCB1 (separately
and combined) a case-control study was performed.
Methods: 72 patients with PAD of the lower limbs under PTA (+/- stent)
and treated with clopidogrel were selected. CYP2C19*2 (rs4244285),
CYP2C19*3 (rs4986893) and ABCB1 (rs1045642) polymorphisms were
genotyped using Taqman allelic discrimination technique to compare post-
operative results.
Results: Out of the 72 patients included in the study, 18 were
CYP2C19*2 allele carries, no patient carried CYP2C19*3 allele and 14 pa-
tients were ABCB1TT genotype. Out of the 72 patients, 25 (34.7%) had an
event during follow up (1 year). Patients with at least some loss of function
had a higher rate of events compared to patients with no loss of function
allele (OR ¼ 5.0, 95% CI 1.75 e14.27, p ¼ 0.003), and patients with some
loss of function allele were associated with a worse Fontaine evolution
(OR ¼ 13.96, 95% CI 4.44e43.82, p < 0.0001). Reduced and non metab-
olizer patients also had a higher rate of events compared to good
metabolizer patients (OR ¼ 4.49, 95% CI 1.25 e13.84, p ¼ 0.009) and a
worse outcome Fontaine grade (OR ¼ 8.31, 95% CI 2.36e29.16;
p ¼ 0.001). However, poor transporter patients didn’t show a statistically
signiﬁcant higher rate of events comparing to good transporters although
they showed a worse Fontaine grade evolution (OR ¼ 4.75, 95% CI 1.32e
17.07, p ¼ 0.017)
Conclusion: Poor metabolizer patients of clopidogrel have a higher
risk of major ischemic events and worst Fontaine grade evolution. Our
results support the role of CYP2C19 and ABCB1 polymorphisms as ge-
netic markers for vascular events in patients with peripheral vascular
disease of the lower limbs undergoing PTA and treated with clopidog-
rel.
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Introduction: Angiogenesis, the sprouting of new capillaries from the
microvasculature, improves blood perfusion of ischemic tissue. Various pro-
angiogenic factors have the potential to stimulate and enhance angio-
genesis. However, due to poor drug delivery and rapid clearance, clinical
trials on pro-angiogenic therapeutics in peripheral arterial disease have
only been marginally successful. We aimed to develop a polymer-based
drug delivery platform enabling local, sustained delivery of pro-angiogenic
